In this video, Nancy U. Lin, MD, highlights practice-changing trials in the HER2-positive metastatic breast cancer space.

FDA designates T-DXd plus pertuzumab as breakthrough therapy for HER2-positive metastatic breast cancer, promising improved ...

AstraZeneca (AZN) announced Enhertu in combination with pertuzumab has been granted Breakthrough Therapy Designation in the U.S. for the first-line treatment of adult patients with unresectable or ...

The FDA granted breakthrough therapy designation to first-line treatment with Enhertu plus Perjeta for unresectable or metastatic HER2+ breast cancer.

The PFS benefit for ENHERTU plus pertuzumab versus THP was consistent across subgroups, including the prespecified stratification factors of de novoor recurrent disease, hormone receptor (HR ...

The safety profile of Enhertu in combination with pertuzumab was consistent with the known profiles of each individual therapy. Enhertu is a specifically engineered HER2-directed DXd antibody drug ...

AstraZeneca's Enhertu shows significant success in late-stage trials as a first-line treatment for HER2-positive metastatic breast cancer. Read more here.

First-line treatment with fam-trastuzumab deruxtecan-nxki + pertuzumab improved PFS in patients with HER2-positive metastatic breast cancer.

SHANGHAI, China & JERSEY CITY, N.J. — Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing ...

Pertuzumab is currently indicated by the FDA for use in combination with: 1) trastuzumab (HERCEPTIN) and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have ...

Adrienne Waks, MD, of Dana-Farber Cancer Institute in Boston, and colleagues conducted a prospective substudy of 22 participants in the ADEPT trial, which is investigating trastuzumab/pertuzumab ...

The multicenter, randomized, double-blind, parallel-controlled phase 3 clinical study (NCT05346224) aimed to compare the efficacy and safety of HLX11 with reference Perjeta® (pertuzumab) as a ...